Published in Vaccine Weekly, January 30th, 2002
The new vaccine is based on Rhein Biotech's Hansenula polymorpha yeast based recombinant hepatitis B antigen (HBsAg), the active ingredient of commercially approved hepatitis B vaccines (Hepavax-Gene, AgB, Biovac B), and Corixa's RC-529 synthetic adjuvant.
The hepatitis B vaccines currently commercially available generally need three injections for full protection. Results of the primary efficacy analyses showed that there were significantly more individuals seroprotected after two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly